179 related articles for article (PubMed ID: 21430111)
1. Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.
Kim YW; Liu TJ; Koul D; Tiao N; Feroze AH; Wang J; Powis G; Yung WK
Neuro Oncol; 2011 Apr; 13(4):367-75. PubMed ID: 21430111
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells.
Harder BG; Peng S; Sereduk CP; Sodoma AM; Kitange GJ; Loftus JC; Sarkaria JN; Tran NL
Mol Med; 2019 Nov; 25(1):49. PubMed ID: 31726966
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Paul-Samojedny M; Pudełko A; Kowalczyk M; Fila-Daniłow A; Suchanek-Raif R; Borkowska P; Kowalski J
BioDrugs; 2016 Apr; 30(2):129-44. PubMed ID: 26902608
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
[TBL] [Abstract][Full Text] [Related]
5. Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development.
Thaker NG; Zhang F; McDonald PR; Shun TY; Lazo JS; Pollack IF
Neurosurg Focus; 2010 Jan; 28(1):E4. PubMed ID: 20043719
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway.
Guan Y; He Y; Lv S; Hou X; Li L; Song J
J Drug Target; 2019 Jan; 27(1):60-66. PubMed ID: 29768063
[TBL] [Abstract][Full Text] [Related]
7. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
Koul D; Shen R; Kim YW; Kondo Y; Lu Y; Bankson J; Ronen SM; Kirkpatrick DL; Powis G; Yung WK
Neuro Oncol; 2010 Jun; 12(6):559-69. PubMed ID: 20156803
[TBL] [Abstract][Full Text] [Related]
8. LIM and SH3 protein 1 regulates cell growth and chemosensitivity of human glioblastoma via the PI3K/AKT pathway.
Zhong C; Chen Y; Tao B; Peng L; Peng T; Yang X; Xia X; Chen L
BMC Cancer; 2018 Jul; 18(1):722. PubMed ID: 29980193
[TBL] [Abstract][Full Text] [Related]
9. PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA.
Nawaz Z; Patil V; Paul Y; Hegde AS; Arivazhagan A; Santosh V; Somasundaram K
Mol Cancer; 2016 Nov; 15(1):74. PubMed ID: 27871300
[TBL] [Abstract][Full Text] [Related]
10. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Johannessen TC; Prestegarden L; Grudic A; Hegi ME; Tysnes BB; Bjerkvig R
Neuro Oncol; 2013 Mar; 15(3):269-78. PubMed ID: 23258843
[TBL] [Abstract][Full Text] [Related]
11. Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.
Gwak HS; Shingu T; Chumbalkar V; Hwang YH; DeJournett R; Latha K; Koul D; Alfred Yung WK; Powis G; Farrell NP; Bögler O
Int J Cancer; 2011 Feb; 128(4):787-96. PubMed ID: 20473884
[TBL] [Abstract][Full Text] [Related]
12. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma.
Xu Y; Stamenkovic I; Yu Q
Cancer Res; 2010 Mar; 70(6):2455-64. PubMed ID: 20197461
[TBL] [Abstract][Full Text] [Related]
13. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
14. High-throughput screening uncovers miRNAs enhancing glioblastoma cell susceptibility to tyrosine kinase inhibitors.
Cunha PP; Costa PM; Morais CM; Lopes IR; Cardoso AM; Cardoso AL; Mano M; Jurado AS; Pedroso de Lima MC
Hum Mol Genet; 2017 Nov; 26(22):4375-4387. PubMed ID: 28973155
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated transfer of siRNA against basic fibroblast growth factor mRNA enhances the sensitivity of glioblastoma cells to chemotherapy.
Feng X; Zhang B; Wang J; Xu X; Lin N; Liu H
Med Oncol; 2011 Mar; 28(1):24-30. PubMed ID: 20221717
[TBL] [Abstract][Full Text] [Related]
17. Targeting the AKT pathway in glioblastoma.
McDowell KA; Riggins GJ; Gallia GL
Curr Pharm Des; 2011; 17(23):2411-20. PubMed ID: 21827416
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data.
Xu D; Zhou D; Bum-Erdene K; Bailey BJ; Sishtla K; Liu S; Wan J; Aryal UK; Lee JA; Wells CD; Fishel ML; Corson TW; Pollok KE; Meroueh SO
ACS Chem Biol; 2020 Jun; 15(6):1424-1444. PubMed ID: 32243127
[TBL] [Abstract][Full Text] [Related]
19. Current clinical development of PI3K pathway inhibitors in glioblastoma.
Wen PY; Lee EQ; Reardon DA; Ligon KL; Alfred Yung WK
Neuro Oncol; 2012 Jul; 14(7):819-29. PubMed ID: 22619466
[TBL] [Abstract][Full Text] [Related]
20. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.
Kanai R; Wakimoto H; Martuza RL; Rabkin SD
Clin Cancer Res; 2011 Jun; 17(11):3686-96. PubMed ID: 21505062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
